newsfilter
← Latest News
GlobeNewswire·

LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration (NMPA)Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic